- Company
- Problems with the most expensive CAR-T treatment Kymriah
- by Mar 26, 2021 05:38am
- The CAR-T treatment Kymriah (Tisagenlecleucel), which is considered the hope of terminal blood cancer patients, was launched in Korea after 4 years, but there are problems to be solved. Kymriah is treated in a completely different way from existing medicines, so it is not easy to calculate the drug price, and at a price of &8361;500 milli
- Company
- Samchundang to start oral insulin clinical trial this year
- by Kim, Jin-Gu Mar 26, 2021 05:37am
- Samchundang Pharm announced its plan to start clinical trial on 'oral insulin' within this year. Also the South Korean company explained that four vaccines were added to the pipeline of the 'S-Pass' platform, a technology converting injection into oral drug. In the case of Eylea (aflibercept) biosimilar, the company expects to complete a
- Company
- The patent dispute for the combination drug Ducarb expanded
- by Kim, Jin-Gu Mar 25, 2021 05:58am
- The patent challenges of 34 domestic companies for Boryung's Dukarb are following one after another. It is analyzed that the expiration of the substance patent of Fimasartan is approaching two years in the future, and it is aiming for the early release of generics for combination drugs including Fimasartan. According to the pharmaceutical
- Company
- ↑Sales of local subsidiaries in Japan & Southeast Asia
- by Kim, Jin-Gu Mar 24, 2021 07:28am
- While the earnings of subsidiaries in China and North America, which were relatively affected by COVID-19, decreased significantly, the performance of local subsidiaries in Japan and Southeast Asia increased relatively. ◆↓20% sales of Beijing Hanmi / ↓13%, Ilyang / ↓12%, China According to the Financial Supervisory Service on th
- Company
- Pneumococcal vaccine Prevenar 13 lowers COVID-19 risk
- by Eo, Yun-Ho Mar 24, 2021 05:46am
- A study found a pneumococcal vaccine Prevenar 13 could lower the risk related to COVID-19. The Kaiser Permanente Southern California (KPSC) has recently presented the study result of the effect of Prevenar 13 (PCV13) on elderly patients’ COVID-19 infection progress. The study was published in the Journal of Infectious Diseases. The s
- Company
- Tagrisso expands benefits as a first-line treatment
- by Mar 24, 2021 05:45am
- Tagrisso, a targeted treatment for EGFR mutant non-small cell lung cancer, is not receiving benefits from the first-line treatment in Korea. The medical staff emphasized the need for Tagrisso's benefit. On the 19th, AstraZeneca Korea held an online press conference to commemorate the 5th anniversary of Tagrisso's postoperative adjuvant ther
- Company
- Domestic approval of Ajovy is imminent
- by Eo, Yun-Ho Mar 23, 2021 06:24am
- The second anti-CGRP mechanism following Emgality is expected to be approved in Korea. According to related industries, Teva Handok is in discussions for domestic approval of Ajovy(Fremanezumab), a migraine treatment targeting Calcitonin gene-related peptide (CGRP). Approval is possible within the first half of the year. The effectiven
- Company
- Who’ll be the 2nd Korean-made COVID-19 drug?
- by Kim, Jin-Gu Mar 23, 2021 06:23am
- Chong Kun Dang’s candidate COVID-19 treatment Nafabeltan has failed to get the South Korean health authority’s conditional approval. As the Ministry of Food and Drug Safety (MFDS) shut the first door of conditional approval to highly anticipated candidate Nafabeltan, the public is now curious of who would be the next second South Kore
- Company
- Big 5 to prescribe a novel antifungal drug Cresemba
- by Eo, Yun-Ho Mar 22, 2021 06:17am
- The Big Five South Korean general hospitals have registered a novel antifungal drug Cresemba for prescription. Pharmaceutical industry sources reported the Drug Committee (DC) at all of the Big Five general hospitals in South Korea, including Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital and Severa
- Company
- Keytruda is expected to expand its indications
- by Eo, Yun-Ho Mar 19, 2021 06:29am
- Keytruda, an immune anticancer drug, is expected to expand its indications for the first-line therapy for colon cancer and esophageal cancer. According to industry sources, MSD Korea recently submitted an application for additional indications about PD-1 inhibitor Keytruda's (Pembrolizumab) ▲MSI-H, microsatellite instability high or dMMR, fi
